Comparative Pharmacology
Head-to-head clinical analysis: CIPRODEX versus SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRODEX versus SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH.
CIPRODEX vs SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication; dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade produces bactericidal effect.
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension: 4 drops into affected ear(s) twice daily for 7 days.
One double-strength tablet (160 mg trimethoprim/800 mg sulfamethoxazole) orally every 12 hours.
None Documented
None Documented
Ciprofloxacin: terminal elimination half-life 3-5 hours (prolonged to 5-10 hours in renal impairment). Dexamethasone: biological half-life 36-54 hours.
Sulfamethoxazole: 9-11 hours; trimethoprim: 8-11 hours. In severe renal impairment (CrCl <15 mL/min), half-life prolongs significantly (up to 30 hours for trimethoprim).
Ciprofloxacin: 50-70% renal (glomerular filtration and tubular secretion), 20-35% biliary/fecal. Dexamethasone: renal elimination of metabolites, <5% unchanged.
Both sulfamethoxazole and trimethoprim are primarily excreted via the kidneys. Sulfamethoxazole: ~30% as unchanged drug, ~50% as N4-acetyl metabolite; trimethoprim: ~80% as unchanged drug. Fecal elimination is minimal (<5%).
Category C
Category D/X
Antibiotic/Corticosteroid Combination (Otic)
Antibiotic